These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9665418)

  • 1. Comparison of seven immunoassays for the quantification of CA 125 antigen in serum.
    Davelaar EM; van Kamp GJ; Verstraeten RA; Kenemans P
    Clin Chem; 1998 Jul; 44(7):1417-22. PubMed ID: 9665418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four 'second generation' immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysis.
    Koper NP; Thomas CM; Massuger LF; Segers MF; Kiemeney LA; Verbeek AL
    Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):617-23. PubMed ID: 9298352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
    Czekierdowski A
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125.
    van Ingen HE; Chan DW; Hubl W; Miyachi H; Molina R; Pitzel L; Ruibal A; Rymer JC; Domke I
    Clin Chem; 1998 Dec; 44(12):2530-6. PubMed ID: 9836722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value.
    Bonfrer JM; Korse CM; Verstraeten RA; van Kamp GJ; Hart GA; Kenemans P
    Clin Chem; 1997 Mar; 43(3):491-7. PubMed ID: 9068593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of five immunoassay procedures for the ovarian carcinoma-associated antigenic determinant CA 125 in serum.
    Yedema KA; Thomas CM; Segers MF; Doesburg WH; Kenemans P
    Eur J Obstet Gynecol Reprod Biol; 1992 Dec; 47(3):245-52. PubMed ID: 1294413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant serum CA 125 values in commercial immunoassays.
    van Kamp GJ; Verstraeten AA; Kenemans P
    Eur J Obstet Gynecol Reprod Biol; 1993 Apr; 49(1-2):99-103. PubMed ID: 8365530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.
    Ruggeri G; Bandiera E; Zanotti L; Belloli S; Ravaggi A; Romani C; Bignotti E; Tassi RA; Tognon G; Galli C; Caimi L; Pecorelli S
    Clin Chim Acta; 2011 Jul; 412(15-16):1447-53. PubMed ID: 21557935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
    Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
    Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
    Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BR-MA, OM-MA, GI-MA and CEA: clinical evaluation using the IMMULITE analyzer.
    van Dalen A
    Tumour Biol; 1999; 20(3):117-29. PubMed ID: 10213919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter evaluation of the Elecsys CA 125 II assay.
    Hubl W; Chan DW; Van Ingen HE; Miyachi H; Molina R; Filella X; Pitzel L; Ruibal A; Rymer JC; Bagnard G; Domke I
    Anticancer Res; 1999; 19(4A):2727-33. PubMed ID: 10470230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer.
    Robertson DM; Stephenson T; Pruysers E; McCloud P; Tsigos A; Groome N; Mamers P; Burger HG
    J Clin Endocrinol Metab; 2002 Feb; 87(2):816-24. PubMed ID: 11836327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic cytokines as tumor markers in gynecological malignancies: a multivariate analysis with ROC curve in endometrial cancer patients.
    Lawicki S; Będkowska GE; Gacuta-Szumarska E; Szmitkowski M
    Growth Factors; 2012 Feb; 30(1):29-36. PubMed ID: 22010785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
    Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
    Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
    Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
    PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy.
    Teh BH; Yong SL; Sim WW; Lau KB; Suharjono HN
    Horm Mol Biol Clin Investig; 2018 Jul; 35(1):. PubMed ID: 30063463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.